title: [Effectiveness of antiinflammatory therapy in patients with interstitial lung diseases using re-assay of biomarker mucin 3EG5].
abstract: OBJECTIVE
  To investigate a potential of a new marker of activity of interstitial pulmonary diseases (IPD)--mucin 3EG5--in monitoring of effectiveness of the antiinflammatory therapy.
  
  
  METHODS
  Serum mucin antigen 3EG5 (glycolyl-sialylated glycoprotein) was assessed with sandwich immunoassay constructed using a monoclonal antibody 3E1.2 (Medical Innovations, Australia) and affinity-purified polyclonal antibody G5 (Xema, Russia) against total mucin antigen family. The level of serum 3EG5 was studied in 16 IPD patients (9 had idiopathic pulmonary fibrosis and 7--chronic hypersensitivity pneumonitis) before and after 6 months of immunosuppressive therapy. By changes in pulmonary function tests during 6 months of steroid treatment all the patients were divided into two groups: responders (a 15% increase in FVC, 20% increase in DLCO and reduction in the PA-aO2 of 5 mm Hg) and nonresponders (worsening or insignificant changes in these indices).
  
  
  RESULTS
  In responders (n = 7) after treatment serum levels of 3EG5 fell from 230 +/- 97 to 88 +/- 40 units/ml (p < 0.01). In nonresponders serum 3EG5 was not different before and after therapy: 249 +/- 153 and 247 +/- 170 units/m, although in this group two patients with unchanged lung function showed a significant decrease in 3EG5, so the accuracy of changes in serum 3EG5 to reflect response to therapy was 88%. There was a significant difference between the posttreatment levels of 3EG5 of the two groups of patients (p = 0.03).
  
  
  CONCLUSIONS
  Successive measurements of serum mucin 3EG5 may be used for monitoring of the response to immunosuppressive therapy in IPD patients.
authors.forename: O E
authors.initials: OE
authors.lastname: Avdeeva
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Lebedin
authors.forename: S N
authors.initials: SN
authors.lastname: Avdeev
authors.forename: A G
authors.initials: AG
authors.lastname: Chuchalin
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal; D015415:Biomarkers / Q000097:blood; D006801:Humans; D007118:Immunoassay; D017563:Lung Diseases, Interstitial / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D009077:Mucins / Q000097:blood* / Q000276:immunology; D012129:Respiratory Function Tests; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D009077:Mucins